Recruitment of participants for clinical trials of “cerebrovascular disease stem cell therapy” for patients with vascular dementia.
【Health Digest | Reporter Choi Min-young】 Cerebrovascular disease strikes unexpectedly. When a blood vessel supplying blood to the brain becomes blocked, a “cerebral infarction” occurs, and when it bursts, a “cerebral hemorrhage” occurs.
Selpia Clinic, a stem cell regeneration clinic, announced on the 23rd that it is recruiting volunteers for a clinical trial to apply regenerative medicine stem cell therapy to treat vascular dementia, a cerebrovascular disease caused by brain tissue damage.
The study targets patients under the age of 75 who have experienced recovery difficulties due to cerebral infarction or cerebral hemorrhage, have vascular dementia lasting more than three months, have shown minimal improvement despite medication, and have not seen any improvement in symptoms.
This study, titled “The Effects of Autologous Blood-Derived Stem Cells on Patients with Vascular Dementia,” will examine the effects of selectively isolating cells from autologous blood and injecting them into the blood vessels that flow to the brain.
The study will examine the effects of autologous blood-derived stem cells on improving dementia symptoms through neuroprotective effects and restoration of brain function.
This clinical trial will utilize Miracell’s advanced stem cell extraction system, “Smart Mcell 2,” which has FDA registration and approval from the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, to extract highly safe stem cells.
The BSC will be used to administer hematopoietic stem cells and various growth factors, including cytokines.
Stem cells are progenitor cells that exist within the body. They are characterized by their outstanding regenerative ability,
restoring damaged tissues to their original function. When stem cells are injected, the cells that migrate to the cerebral blood vessels are expected to regenerate cerebral vascular endothelial damage and strengthen existing blood vessels.
The clinical trial uses autologous stem cells, so there are no side effects or costs.
August 23, 2022